ELQ-598, a prodrug, is converted to the active drug ELQ-596 upon oral administration. It demonstrates potent parasitic growth inhibition capabilities (IC50 = 37 nM) and shows low toxicity towards human cells (IC50 = 19 μM). ELQ-598 can be used for research into babesiosis [1].

ELQ-598 at a dosage of 10 mg/kg, administered orally from the third to the seventh day post-infection, effectively eradicates Babesia duncani infection in C3H mice and Babesia microti infection in mice. Additionally, combining ELQ-598 with atovaquone at the same dosage eradicates Babesia duncani in C3H/HeJ mice and Babesia microti in SCID mice. All treated mice survived without recurrence of infection, indicating the potent synergistic effect of the drug combination.